相关实验视频

Updated: Mar 6, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

在DLBCL中免疫检查点PD-1,PD-L1和CTLA-4的多态性和过度表达:从病例控制研究中的生物标志物见解

Habibe Sema Arslan Unal^1,2, Ozan Salim³, Unal Atas³

¹Department of Medical Genetics, School of Medicine, Kirsehir Ahi Evran University, Kirsehir, Turkey.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

|March 5, 2026

概括

像PD-1,PD-L1和CTLA-4这样的免疫检查点在扩散性大B细胞淋巴瘤 (DLBCL) 中过度表达,这表明它在免疫逃逸中发挥了作用. 这些检查点中的遗传变异也可能影响DLBCL的进展,并可以作为生物标志物.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
遗传学是一个遗传学.

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 在治疗结果中表现出显著的异质性.
免疫检查点 (PD-1,PD-L1,CTLA-4) 是抗瘤免疫和治疗点的关键调节者.
研究DLBCL病原体中的这些检查点的遗传变异和表达是必不可少的.

研究的目的:

检查PD-1,PD-L1和CTLA-4基因多态性及其在DLBCL中的表达水平之间的关联.
确定这些免疫检查点在DLBCL发展和进展中的潜在作用.

主要方法:

一项涉及20名DLBCL患者和20名健康对照者的病例控制研究.
在PD-1 (rs2227981),PD-L1 (rs4143815) 和CTLA-4 (rs231775) 中单核酸多态 (SNPs) 的基因定型.
定量实时PCR (RT-qPCR) 用于mRNA表达和流细胞计,用于免疫细胞上的蛋白质分析.

主要成果:

与对照组相比,DLBCL患者观察到PD-1,PD-L1和CTLA-4的mRNA水平明显升高.
在PD-1,PD-L1和CTLA-4中的特定SNP与改变的基因表达有关.
流细胞计显示DLBCL患者CD4+PD-1+和CD4+PD-L1+细胞的百分比增加.

结论:

过度表达PD-1,PD-L1和CTLA-4,以及相关的遗传变异,可能会导致DLBCL的免疫逃避和疾病进展.
这些免疫检查点显示出作为DLBCL的预后生物标志物的潜力.
需要进一步的大规模研究来验证这些发现,以便开发个性化疗法.

关键词:

在 CTLA-4 中.扩散大的B细胞淋巴瘤.基因表达基因表达基因表达在PD-1中使用PD-1.在PD-L1中.

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...